AJPH
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

AJPH First Look, published online ahead of print Jul 27, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
AJPH.2006.091025v1
96/9/1534-a    most recent
Right arrow Submit a response
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rusen, I. D.
Right arrow Articles by Enarson, D. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Rusen, I. D.
Right arrow Articles by Enarson, D. A.
Related Collections
Right arrow Global Health
Right arrow Access to Care
Right arrow Tuberculosis
September 2006, Vol 96, No. 9 | American Journal of Public Health 1534-1535
© 2006 American Public Health Association
DOI: 10.2105/AJPH.2006.091025

LETTER

RUSEN AND ENARSON RESPOND

I. D. Rusen, MD, MSc and Donald A. Enarson, MD

The authors are with the Department of Tuberculosis and Lung Health, International Union Against Tuberculosis and Lung Disease (The Union), Paris, France.

Correspondence: Requests for reprints should be sent to I. D. Rusen, MD, MSc, Department of Tuberculosis and Lung Health, International Union Against Tuberculosis and Lung Disease, 68 boulevard Saint Michel, 75006 Paris, France (e-mail: irusen@iuatld.org).

Because this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

We appreciate Lauer and Birn’s interest in our article. However, many of the concerns they raise are speculative and are not consistent with the operational reality of FIDELIS. First, the authors question the local nature of the FIDELIS projects and suggest that FIDELIS is most accessible to organizations affiliated with developed countries. In fact, the projects approved to date are truly local in nature; internationally associated nongovernmental organizations and academic institutions have been awarded only 7 of 32 projects approved in rounds 1 through 4.

Second, Lauer and Birn wonder whether the members of the "existing TB control structure" who . . . [Full Text]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Public Health Association